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MrsD from Bacillus sp. HIL-Y85/54728 is a member of the
HFCD (homo-oligomeric ¯avin-containing Cys decarboxy-
lases) family of ¯avoproteins and is involved in the biosynth-
esis of the lantibiotic mersacidin. It catalyses the oxidative
decarboxylation of the C-terminal cysteine residue of the
MrsA precursor peptide of mersacidin, yielding a (Z)-enethiol
intermediate as the ®rst step in the formation of the unusual
amino acid S-[(Z)-2-aminovinyl]-methyl-d-cysteine. Surpris-
ingly, MrsD was found to bind FAD, in contrast to the three
other characterized members of the HFCD family, which bind
FMN. To determine the molecular discriminators of FAD
binding within the HFCD family, the crystal structure of MrsD
was analyzed at a resolution of 2.54 AÊ . Crystals of space group
F432 contain one MrsD monomer in the asymmetric unit.
However, a Patterson search with EpiD-derived models failed.
Based on the consideration that the dodecameric MrsD
particle of tetrahedral symmetry resembles the quaternary
structure of EpiD, rotational and translational parameters
were derived from the geometric consideration that the MrsD
dodecamer is generated from a monomer by crystallographic
symmetry around the position (1/4, 1/4, 1/4) of the unit cell. A
structural comparison with the FMN-binding members of the
HFCD family EpiD and AtHAL3a shows conserved sequence
motifs in contact with the ¯avin's pyrimidine ring but
divergent environments for the dimethylbenzene ring of the
isoalloxazine moiety. The position of the ribityl chain differs in
MrsD from that found in EpiD and AtHAL3a. However, the
FMN-phosphate binding sites are also highly conserved in
their exact positions. In all three cases, the ¯avin cofactor is
bound to a structurally conserved region of the Rossmann-
fold monomer, exposing its Re side for catalysis. The adenosyl
phosphate of FAD is anchored in a well de®ned binding site
and the adenosine moieties are oriented towards the interior
of the hollow particle, where three of them pack against each
other around the threefold axis of a trimeric facet.
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1. Introduction
The lantibiotic mersacidin is active against methicillin-
resistant Staphylococcus aureus strains (Chatterjee et al., 1992)
and inhibits the transglycosylation reaction in peptidoglycan
biosynthesis by binding to the cell-wall precursor lipid II
(BroÈ tz et al., 1997, 1998). Lantibiotics are ribosomally
synthesized and post-translationally modi®ed peptides that
contain the thioether amino acid lanthionine as a character-
istic building block (Schnell et al., 1988). In mersacidin,
epidermin, gallidermin and some of the mutacins, unsaturated
thioether bridges are present (Allgaier et al., 1985; Kellner et
al., 1988; Minami et al., 1994; Mota-Meira et al., 1997; Qi et al.,
1999, 2000; Smith et al., 2000). Biosynthesis of the carboxy-
terminal S-[(Z)-2-aminovinyl]-3-methyl-d-cysteine residue of
mersacidin occurs in two steps. The FAD-dependent ¯avo-
protein MrsD catalyzes the oxidative decarboxylation of the
COOH-terminal cysteine residue of the mersacidin precursor
peptide MrsA to an aminoenethiol structure (Fig. 1) (Majer et
al., 2002). The unsaturated thioether is then formed by addi-
tion of the enethiol group to the didehydrobutyrine residue at
position +15 of MrsA which is introduced by dehydration of
Thr. The homologous enzyme EpiD, which is an FMN-
dependent and not an FAD-dependent enzyme, catalyzes the
oxidative decarboxylation of the peptidyl-cysteine precursor
peptide EpiA (Kupke et al., 1992, 1994, 1995). MrsD and EpiD
belong to a new family of ¯avoproteins that was named HFCD
(homo-oligomeric ¯avin-containing Cys decarboxylases;
Blaesse et al., 2000; Kupke, 2002a; Kupke et al., 2000b). Other
members of this ¯avoprotein family include the ¯avoenzymes
Dfp from eubacteria (Kupke et al., 2000b; Spitzer et al., 1988;
Spitzer & Weiss, 1985) and AtHAL3a from Arabidopsis
thaliana (Espinosa-Ruiz et al., 1999). Both catalyze the
decarboxylation of (R)-40-phospho-N-pantothenoylcysteine
(PPC) to 40-phosphopantetheine (PP) (Kupke, 2001; Kupke et
al., 2000b, 2001; Strauss & Begley, 2001), a reaction introdu-
cing the reactive cysteamine residue of coenzyme A. However,
Dfp is a bifunctional enzyme: the COOH-terminal CoaB
domain catalyzes the synthesis of PPC from 40-phospho-
pantothenate and l-cysteine using cytidine-50-triphosphate as
the activating nucleotide (Kupke, 2002b; Strauss et al., 2001),
whereas the PPC decarboxylase activity resides in the amino-
terminal CoaC domain (Kupke, 2001). The decarboxylation of
PPC is a two-step reaction. In the ®rst half-reaction PPC is
oxidatively decarboxylated to the 40-phosphopantothenoyl-
aminoethene intermediate, which is reduced to 40-phospho-
pantetheine in the second half-reaction (HernaÂndez-Acosta et
al., 2002; Steinbacher et al., 2003).
The crystal structures of EpiD, of the active-site mutant
EpiD H67N with bound pentapeptide substrate DSYTC
(Blaesse et al., 2000), of AtHal3a (Albert et al., 2000) and of
the AtHAL3a mutant C175S with bound oxidatively decar-
boxylated intermediate pantothenoyl-aminoethenethiol
(Steinbacher et al., 2003) have recently been determined.
These structures gave insight into the reaction mechanism, the
substrate-binding mode and the substrate speci®city of the
HFCD proteins.
EpiD forms dodecamers with trimers
disposed on the vertices of a tetrahedron.
Each of the monomers consists of a single
domain with a Rossmann-type fold.
Oligomer formation is essential for binding
of the ¯avin mononucleotide cofactor and
the substrate, which is buried by an other-
wise disordered substrate-recognition
clamp. The FMN cofactor can be assigned to
one subunit that provides the majority of
the interactions and is buried at the center
of the trimer side face contacting three
subunits. The sequence motifs PASANT and
PXMNXXMW which are characteristic for
the HFCD proteins are involved in binding the cofactor (and
the substrate). EpiD shares the Rossmann-type fold with
¯avodoxin-like proteins, although there is no sequence simi-
larity. Superposition of ¯avodoxin and EpiD showed that the
FMN cofactors bind to topologically similar positions.
However, the ribityl moieties have different orientations and
the FMN molecules expose different sides. The substrate-
binding clamp of EpiD comprises residues Pro143±Met162
and forms a three-stranded -sheet with the substrate peptide.
The C-terminal cysteine residue of the substrate is ®xed in the
vicinity of the isoalloxazine ring of the FMN cofactor and its
carboxylate group is hydrogen-bonded to Ser152 and Asn117
of the PXMNXXMW motif. Based on the geometry of the
EpiD±substrate complex, we suggested that the side chain of
the substrate cysteine residue is oxidized to a thioaldehyde
structure. This thioaldehyde intermediate spontaneously
decarboxylates, forming the enethiolate structure of the
reaction product (Blaesse et al., 2000).
Here, we present the structure of MrsD, the ®rst char-
acterized FAD-containing HFCD protein, and compare the
known structures of HFCD proteins with respect to binding of
the cofactor and the substrate. Modelling of an MrsD±
substrate peptide complex explains the different substrate
speci®cities of EpiD and MrsD. In total, the crystal structures
of three HFCD proteins are now known, giving insight into the
relationship between the function, sequence and structure of
this new protein family. The work published here and in
related papers shows how the side chain of cysteine residues is
converted to a thioaldehyde structure, establishing new
biochemistry of the thiol group.
2. Experimental
2.1. Expression, purification and crystallization
The MrsD protein was overexpressed in recombinant
Escherichia coli M15 pREP4 harbouring the mrsD gene in the
plasmid pQE12 as decribed previously (Majer et al., 2002).
Brie¯y, cells were grown at 310 K in 5 l Luria±Bertani medium
to an OD600nm of 0.6. Protein expression was induced by
addition of 1 mM isopropyl--d-thiogalactopyranoside
(IPTG). After 5 h, the cells were harvested by centrifugation,
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Figure 1
Reaction performed by MrsD. The C-terminal cysteine residue of the precursor peptide MrsA
is oxidized by FAD to form a putative thioaldehyde intermediate that decarboxylates
spontaneously. The resulting enethiol structure forms a thioether by adding to a double bond
generated by dehydration of a threonine residue, which results in the unusual amino acid
S-[(Z)-2-aminovinyl]-3-methyl-d-cysteine.
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resuspended in 100 ml 10 mM Tris±HCl pH 8.0 and lysed by
soni®cation.
After removal of the insoluble cell debris, the clear super-
natant was applied to a Q-Sepharose anion-exchange column
(100 ml) equilibrated with 20 mM NaCl in 10 mM Tris±HCl
pH 8.0. After washing with the same buffer, MrsD was eluted
with 60 mM NaCl in 10 mM Tris±HCl pH 8.0. The pooled
protein was applied to a hydoxyapatite column (50 ml,
MacroPrep ceramic hydroxyapatite 40 mm; BioRad) equili-
brated with 20 mM potassium phosphate in 20 mM Tris±HCl,
150 mM NaCl pH 8.0, washed with the equilibration buffer
and eluted in a linear gradient to 500 mM potassium phos-
phate in 20 mM Tris±HCl, 150 mM NaCl pH 8.0. The pooled
fractions were dialysed against 20 mM Tris±HCl, 150 mM
NaCl pH 8.0 and concentrated to 20 mg mlÿ1 by ultra®ltration.
Aliquots of 0.3±0.5 ml were loaded onto a Superose 12 column
(Pharmacia, HR 30/10) and eluted at a rate of 0.3±
0.4 ml minÿ1. The pooled fractions were dialysed against
50 mM NaCl in 20 mM Tris±HCl pH 8.0 and concentrated to a
®nal concentration of 10 mg mlÿ1.
Initial screening for crystallization conditions was
performed with factorial solutions (Hampton Research
Crystal Screens I, II and Cryo), which yielded two conditions
for similar cubic crystal forms. Condition I (1.6 M KNaHPO4
in 0.1 M HEPES pH 7.5) yielded crystals with a rather low
FAD occupancy, presumably because the phosphate ions were
competing with the FAD phosphates. Crystals from condition
II (1.2 M potassium/sodium tartrate, 0.1 M Tris±HCl pH 9.1)
could be grown in the presence of 2 mM FAD and showed a
signi®cantly higher FAD occupancy. Therefore, a crystal from
the tartrate condition with space group F432 and unit-cell
parameters a = b = c = 191.8 AÊ was used for structure deter-
mination.
2.2. Data collection, structure solution and refinement
For data collection under cryogenic conditions, the crystals
from condition II were transferred to a buffer additionally
containing 30%(v/v) glycerol. Data were collected at beamline
BW6 at DESY in Hamburg with a MAR Research CCD
detector from a crystal cooled to 100 K with an Oxford
Cryostream. Data were integrated, scaled and merged with the
HKL suite (Otwinowski & Minor, 1997). The crystals
contained one molecule in the asymmetric unit and had a
solvent content of about 67%. Patterson search methods with
the EpiD protomer were unsuccessful despite its high struc-
tural similarity, as is sometimes encountered in high-symmetry
space groups. The cubic space group F432 displays special
positions of both octahedral and tetrahedral symmetry. As a
tetrahedral particle was expected for MrsD, similar to EpiD,
the EpiD dodecamer was oriented according to the crystal-
lographic symmetry operators and its centre of mass trans-
lated to a special position with tetrahedral symmetry.
The polyalanine model derived from this manually placed
EpiD monomer re®ned readily and could be completed by
iterative rounds of model building with MAIN (Turk, 1992)
and crystallographic re®nement with CNS (BruÈ nger et al.,
1998) using a test set of 5% of the re¯ections for cross-
validation using the maximum-likelihood target using ampli-
tudes. The structure displays good stereochemical parameters
as estimated by the program PROCHECK (Laskowski et al.,
1993). 91% of the residues were found in the most favoured
region of the Ramachandran plot, 9% in additional allowed
regions and no residues in generously allowed or disallowed
regions. Figures were prepared with BOBSCRIPT (Esnouf,
1997).
3. Results and discussion
3.1. Overall structure and oligomeric assembly
MrsD has been crystallized in the cubic space group F432
with one monomer in the asymmetric unit. As the dodeca-
meric oligomer in these crystals is generated by crystallo-
graphic symmetry, the structure could be solved by placing the
EpiD monomer based on geometric considerations. The
crystal structure of MrsD has been re®ned at 2.54 AÊ resolution
to a crystallographic R factor of 22.2% (Rfree = 25.7%)
(Table 1). The model consists of residues Ile3±Met155 and
Arg168±Lys185. The disordered residues Ala156±Asn167 are
part of the putative substrate-binding clamp that embraces the
substrate in an extended conformation. Complete disorder of
the binding clamp in the absence of substrate has also been
observed for the HFCD proteins EpiD (Blaesse et al., 2000)
and AtHAL3a (Albert et al., 2000; Steinbacher et al., 2003).
The oligomeric assembly of MrsD (Fig. 2) closely resembles
that of EpiD, which has been described in detail (Blaesse et al.,
2000).
The monomer structure of MrsD is composed of classical
mononucleotide-binding folds ®rst observed in NADH-
binding proteins (Rossmann et al., 1974). It shares this fold
with the FMN-binding homologues EpiD (Blaesse et al., 2000)
and AtHAL3a (Albert et al., 2000; Steinbacher et al., 2003)
Table 1
Data-collection and re®nement statistics.
Values in parentheses are for the last resolution shell.
Data collection
Unit-cell parameter (AÊ ) a = 191.8
Limiting resolution (AÊ ) 2.54 (2.54-2.68)
Re¯ections 10384
Rmerge² (%) 4.8 (32.5)
hIi/(I) 24.2 (5.4)
Redundancy 6.7 (6.8)
Completeness (%) 99.4 (99.5)
Re®nement
Resolution range (AÊ ) 20±2.54
Re¯ections (working set) 9815 [93.8%]
Re¯ections (test set) 529 [5.1%]
Rcryst³ (%) 22.2
Rfree§ (%) 25.7
Non-H protein atoms 1345
FAD atoms 53
Solvent molecules 69
R.m.s.d. bond length (AÊ ) 0.0105
R.m.s.d. bond angle () 1.19
² Rmerge =
P
hkl 
P
i jIi ÿ hIij=
P
i Ii. ³ Rcryst =
P
hkl
jFobsj ÿ kjFcalcj=Phkl jFobsj for
hkl in the working set. § Rfree =
PjFobs ÿ kjFcalcj=P jFobsj for hkl in the test set.
from the HFCD family. Their structures are composed of six
parallel -strands interspersed by -helices that appear on
both sides of the central -sheet. The monomer shows internal
twofold topological symmetry and is built up from two halves
known as Rossmann folds, 11223 and 44556,
with a crossover -helix (3) connecting 3 and 4. The
-helix 4 is split into two characteristic helices that are
involved in oligomerizaton in the HFCD family. Variations of
this fold are found in FAD-binding proteins with respect to the
second Rossmann fold or the crossover -helix as well as in
proteins that bind FMN or NADPH (Rao & Rossmann, 1973;
Schulz & Schirmer, 1974; Dym & Eisenberg, 2001). In all cases
the cofactor is bound at the C-terminal end of the central
-sheet.
All three known HFCD structures can be superimposed
very well despite the rather low sequence homology of only
30.4% over 158 amino-acid residues between MrsD and EpiD
and of 27.9% for 154 amino-acid residues between MrsD and
AtHAL3a (Fig. 3). The substrate-binding clamps of the LanD
proteins EpiD, MrsD (Pro151±Leu170) and MutD are four
residues longer than that of the PPC
decarboxylases AtHAL3a and Dfp (CoaC)
(Blaesse et al., 2000). Deviations are also
observed for the irregular -helix 2 from
Leu49 to Asp60 of MrsD. A major differ-
ence occurs around the loop from Glu65 to
His73 in MrsD, which is involved in a dimer
contact between trimers in dodecameric
assemblies. This loop is longer in AtHAL3a
to substitute for this dimer contact (Albert
et al., 2000; Steinbacher et al., 2003). In
MrsD, Glu65 and His66 of this loop contri-
bute to the binding of the adenine moiety of
FAD. In addition, the C-terminal helix that
anchors the substrate-binding loop to the
protein core shows certain variability. It is
not surprising that the central -sheets and
adjacent isoalloxazine-binding loops show
the highest degree of structural conserva-
tion displayed by the characteristic signa-
ture sequences PASANT (4±4 loop) and
PXMNXXMW (5±5 loop) of the HFCD
proteins.
3.2. FAD binding site
The FAD cofactor of MrsD is completely
de®ned by electron density (Fig. 4). It is
buried between two neighbouring subunits
of a trimeric facet in such a way that the
adenosyl moiety points into the central
cavity of the oligomer (Fig. 5). Surprisingly,
FAD is not more tightly bound to MrsD
than FMN to EpiD and the ¯avin cofactor is
even partially lost during puri®cation of
MrsD. A major difference in the iso-
alloxazine-binding sites is the weak support
for the dimethyzlbenzene ring in MrsD by
Leu49 (C6ÐC1, 4.3 AÊ ; C7MÐC2, 3.8 AÊ )
and Thr45 (C9ÐC, 4.4 AÊ ) compared with
Phe43 in EpiD, and Phe59 and Trp78 in
AtHAL3a, respectively. In EpiD and
AtHAL3a these residues create a rigid
platform for the dimethylbenzene moiety.
This results in slightly different positions of
the dimethylbenzene moiety in MrsD which
is compensated for by a different confor-
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Figure 2
Three-dimensional structure of MrsD. Dodecamer structure viewed along the twofold (a) and
both directions of the polar threefold (c and d) axes. The centres of gravity of each trimer are
connected by pink rods to indicate the tetrahedral symmetry.
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mation of the ribityl chain (Fig. 5a), but also results in partial
disorder of the dimethylbenzene moiety in MrsD as seen in
the electron density (Fig. 4). It should be noted that for
entropic reasons partial disorder is not automatically related
to lower af®nity (Forman-Kay, 1999). On the other hand, it
may be argued that the weaker contacts between the isoal-
loxazine moiety of FAD and MrsD are partially compensated
by favourable contacts of the adenosylphosphate moiety in
order to result in an overall suf®cient binding of the ¯avin
cofactor. Unfortunately, the various contributions cannot be
dissected in a simple way (Gohlke & Klebe, 2002). The resi-
dues supporting the dimethylbenzene ring are implicated in
in¯uencing the redox potential of the ¯avin cofactor (Fraaije
& Mattevi, 2000). No data are available on the redox potential
of any HFCD protein; however, all representatives are able to
oxidize a thiol group. It cannot be ruled out that modulation of
the redox potential by altering the environment of the dime-
thylbenzene ring also contributes to preventing the reduction
of the enethiol intermediate in LanD proteins.
The FMN phosphate-binding sites of all three available
structures coincide almost exactly when superimposing the
entire structures without special emphasis on the ¯avin-
binding sites (Fig. 5a). It is well documented that phosphate
binding in Rossmann-fold proteins is associated with
conserved sequence motifs (Dym & Eisenberg, 2001), but in
other proteins such as TIM-barrel proteins it is associated with
the so-called standard phosphate-binding motif (SPB; Nagano
et al., 2002). In HFCD proteins the FMN phosphate is bound
by the PASANT motif, which includes Thr91 and Asn93 in
MrsD. The side chains of Thr91 and Asn93 bind to one
phosphate oxygen (Fig. 5a). The adenosyl-phosphate of FAD
is tightly bound to both the backbone carbonyl and the side-
chain hydroxyl of Thr45. Interestingly, Ser39 of EpiD and
Ser55 of AtHAL3a are present at the same position. The side-
chain hydroxyl of Ser39 is shifted by 1.3 AÊ ,
whereas that of Ser55 is found at an almost
identical position. A second well de®ned
contact is formed to the side chain of
Asn105, which is Asn97 in EpiD and
Asn120 in AtHAL3a and is shifted by 1.3
and 1.6 AÊ , respectively. Therefore, no
signi®cant sequence difference can be seen
between the adenosyl-phosphate-binding
site of MrsD and the corresponding posi-
tions in EpiD and AtHAL3a. A major
source of stabilization of FAD binding can
be seen in the tight packing of three
neighbouring FAD molecules along the
symmetry axis of the molecule including
hydrogen bonds between N7 (3.1 AÊ ) and
N6 (2.9 AÊ ) of the adenosine and O2 of the
neighbouring pyranose. In addition,
Met104* (where * denotes residues from
the neighbouring subunit) packs against the
pyranose ring, whereas Lys44 packs against
the adenine moiety. Met104* is unique to
MrsD, as EpiD has Asp96* and AtHAL3a
has Asp119* at this position. Lys44 of MrsD
is also found in AtHAL3a (Lys54), whereas
it is replaced by Pro38 in EpiD. However, in
all cases a tight van der Waals packing with
the adenosine moiety seems possible. A
major difference in backbone position and
sequence is seen around Glu65*±His66*.
Glu65* contacts O3 of the pyranose and
His66* is involved in a van der Waals
contact (4.6 AÊ ) to the adenine moiety. The
sequences are Asp74*±Glu75* in EpiD and
Glu59±Ile60* in AtHAL3a. In summary, the
surprising ®nding that MrsD binds FAD
and not FMN as do EpiD, AtHAL3a or Dfp
cannot be explained by a single structural
reason. Instead, it has to be assumed that a
larger number of small contributions add up
Figure 4
Electron density of FAD bound to MrsD at 2.54 AÊ resolution. (a) Fo ÿ Fc simulated-annealing
omit electron density contoured at 2.5. (b) Final 2Fo ÿ Fc electron density contoured at 1.
Figure 3
Superposition of HFCD monomers. MrsD is shown in green and FAD bound to it as a yellow
ball-and-stick model. EpiD, the substrate pentapeptide and FMN are shown in red. AtHAL3a,
the reaction intermediate pantothenoyl-aminoethenethiol bound to it and FMNH2 are depicted
in blue. SBC denotes the substrate-binding clamp and OLIG the loop in AtHAL3a that
substitutes for a neighbouring subunit from another trimer in the dodecameric assemblies of
EpiD and MrsD.
to a substantial increase in af®nity for FAD compared with
FMN.
3.3. Comparison with other FAD-binding proteins
A recent survey of FAD-binding proteins identi®ed four
family folds, which are exempli®ed by glutathione reductase
(GR), ferredoxin reductase (FR), p-cresol methylhydroxylase
(PCMH) and pyruvate oxidase (PO) (Dym & Eisenberg,
2001). This study also demonstrated variability in FAD
binding, with no single protein `pharmacophore' and the
involvement of highly conserved sequence motifs in pyro-
phosphate binding that allow the identi®cation of phosphate-
binding proteins. Searching the PDB with the program DALI
(Dietmann et al., 2001) shows MrsD has closest similarity to
the pyruvate oxidase family of the four FAD-binding families.
The FAD-binding domain of pyruvate
oxidase (PDB code 1pox; Muller et al.,
1994) can be superimposed onto MrsD with
an r.m.s. deviation of 3.5 AÊ for 113 residues
and with a Z score of 4.5 (Fig. 6). Inter-
estingly, the FAD cofactor is bound with
opposite directionality, e.g. the MrsD
isoalloxazine ring binds approximately
where the adenosine moiety is located in
pyruvate oxidase. Both proteins share a
phosphate-binding site with only 1.3 AÊ
displacement of the phosphate atoms.
However, this site is occupied by the ¯avin
phosphate in MrsD, whereas in pyruvate
oxidase the adenosyl-phosphate is present.
Common properties of this conserved
phosphate-binding site include the back-
bone amide of Gly17 (MrsD) and Ile221
(PO), and the side chains of Thr43 (MrsD)
and Thr244 (PO). Lower similarities are
detected for ferredoxin reductase (Z score
3.9, r.m.s.d. 3.0 AÊ for 88 residues) and
glutathione reductase (Z score 3.0, r.m.s.d.
4.1 AÊ for 100 residues). As can be expected
from the utterly different folding topology,
no representatives of the PCMH family
showed up in the search. This lower simi-
larity to FAD-binding Rossmann-fold
proteins is not surprising, as the HFCD
family shows a higher structural similarity
to FMN-binding proteins such as ¯avo-
doxin (Blaesse et al., 2000).
3.4. Substrate binding
HFCD proteins act on terminal cysteine
residues with free carboxylate groups. Two
reactions have been characterized so far.
Either a decarboxylation without overall
net change of the redox state occurs (PPC
decarboxylases; Kupke et al., 2000a, 2001)
or the substrate is oxidatively decarboxy-
lated, resulting in an enethiol group (LanD
proteins; Kempter et al., 1996; Kupke et al.,
1994). In both cases, the reaction is likely to
start with the oxidation of the thiol group
to a thioaldehyde which spontaneously
decarboxylates to the enethiolate structure.
This enethiol intermediate is then reduced
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Figure 6
Superposition of MrsD and the FAD-binding domain of pyruvate oxidase (residues 213±340).
The FAD cofactors are bound with opposite directionality in extended conformations. Pyruvate
oxidase in shown in blue and MrsD in green, including the modelled substrate-binding clamp
and the substrate peptide (thin ball-and-stick model in red). The MrsD FAD is shown in red and
the pyruvate oxidase FAD in blue. Both structures share a conserved phosphate-binding site.
Figure 5
Interactions between MrsD and FAD. (a) FAD is shown in pink. Thr91 and Asn93 are part of
the conserved PASANT motif; Met128 belongs to the PXMNXXMW motif. FMN bound to
EpiD is in light blue and AtHAL3a is in turquoise. The orientation is identical to Fig. 3. (b) View
from the centre of the dodecamer along the threefold axis.
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by the PPC decarboxylases but not the LanD enzymes,
reoxidizing the ¯avin cofactor which was reduced in the ®rst
step (HernaÂndez-Acosta et al., 2002). The ability of PPC
decaboxylases to reduce the enethiol intermediate is ascribed
to the precise positioning of the intermediate with respect to
the enzyme and the presence of a cysteine residue that acts as
a proton source during the reduction (Steinbacher et al., 2003).
The LanD proteins EpiD, MrsD and MutD share the peptidyl-
cysteine nature of their substrates and have highly homo-
logous substrate-binding clamps of identical lengths. There-
fore, it is reasonable to assume that substrate recognition is
also quite similar, which allows modeling of the MrsD complex
based on the EpiD±substrate complex. The substrate speci®-
city of EpiD has been probed extensively (Kupke et al., 1994,
1995; Majer et al., 2002; Schmid et al., 2002), yielding a
consensus sequence [(Cys)/Val/Ile/Leu/(Met)/Phe/Tyr/Trp]-
[Ala/Ser/Val/Thr/Cys/(Ile/Leu)]-Cys for the three C-terminal
positions. EpiD and MrsD have different substrate speci®cities
and the substrate peptides EpiA and MrsA were not inter-
changeable (Majer et al., 2002). A major determinant of EpiD
substrates is a large hydrophobic residue in the penultimate
position. In the native substrate EpiA a tyrosine residue is
present at this position, whereas in MrsA this residue is
cysteine. It was recently shown that, in principle, EpiD also
accepts a cysteine residue at this position, but the substrate
peptide SFNSCCC was only very inef®ciently oxidatively
decarboxylated (Schmid et al., 2002).
Based on the EpiD±substrate complex (Blaesse et al., 2000),
a model for MrsD substrate recognition can be obtained
(Fig. 7). The C-terminus of the MrsD substrate MrsA has the
sequence Ser-Glu-Cys-Ile-Cys. Compared with the peptide
used in the EpiD complex (Asp-Ser-Tyr-Thr-Cys), a major
difference is the requirement for a large hydrophobic residue
(Tyr) at the ÿ3 position of the EpiD substrate that is replaced
by Cys in MrsA. The residue at ÿ2 is Ile in MrsA but is
preferentially a small and/or hydrophilic residue in an EpiD
substrate. The larger side chain of Ile in MrsA is compensated
for by the exchange of Ser148 (EpiD) for Ala156 in the
substrate-recognition clamp. However, Ile
can also be accepted by EpiD at that posi-
tion with lower ef®ciency. A major differ-
ence is the replacement of the large
hydrophobic residue at positionÿ3 in EpiA
by the signi®cantly smaller Cys in MrsA.
The theoretical model predicts that this
residue is recognized in a hydrophobic
pocket formed by Ile19, Phe157 from the
substrate-binding clamp and Phe58** of
MrsD (** denotes residues related by a
twofold axis from a neighbouring trimer).
Phe157 is predicted to contact Leu29**. It is
a striking feature of substrate recognition in
HFCD proteins that this speci®city pocket
is not static and preformed, as often
observed in proteases, but that this binding
site is generated during the dynamic process
of substrate binding. The speci®city pocket
of MrsD is smaller than that of EpiD owing to the replacement
of Val23 (EpiD) by Leu29 (MrsD).
Both structures have an asparagine residue in common that
is involved in orienting the C-terminal carboxylate group
(Asn117 in EpiD and Asn125 in MrsD) and a hydrophobic
residue (Ile68 in EpiD and Val76 in MrsD) that packs against
the thiol methylene groups of the terminal cysteine residue.
The PPC decarboxylase AtHAL3a complexed to the enethiol
reaction intermediate also shows these active-site character-
istics (Ile91 and Asn142; Steinbacher et al., 2003).
3.5. Conclusions
MrsD represents the third structure of the HFCD family of
¯avoproteins to be described. The members of this novel
family of ¯avoproteins share a trimeric building block
composed of Rossmann-fold type monomers that bind their
¯avin cofactor at the interface of two subunits. In the case of
the plant PPC decarboxylase AtHAL3a from A. thaliana,
these trimers represent the functional oligomeric state.
However, four of the trimers can further assemble to form
dodecamers as observed for EpiD and MrsD. Similar do-
decamers probably represent the core of the E. coli Dfp
protein which is composed of bifunctional monomers. In Dfp,
the PPC decarboxylase activity resides in the N-terminal
domain (CoaC) homologous to HFCD proteins, whereas the
unrelated C-terminal domain (CoaB) harbours the PPC
synthase activity.
The binding of FAD to MrsD cannot be ascribed to a single
structural feature when comparing it with the FMN-binding
proteins EpiD and AtHAL3a. It is assumed to be the result of
a larger number of rather small contributions. It is, however,
an unusual feature of FAD binding to MrsD that the adenine
moiety has no well de®ned binding site provided by the
protein. Major contacts are formed by the tight packing of
three adenosine moieties along the threefold axis of the
trimeric facets of the dodecamer.
The HFCD family of ¯avoproteins can be seen as paradigm
of variability within homologous proteins. From sequence
Figure 7
Theoretical model of the substrate complex. The peptide NH2-Ser1-Glu2-Cys3-Ile4-Cys5-
COOH which represents the COOH-terminal pentapeptide of MrsA and the substrate-binding
clamp (dark blue) were modelled as determined in the EpiD pentapeptide complex (Blaesse et
al., 2000). The speci®city pocket for the cysteine residue Cys3 is formed by Phe58, Ile19 and
Phe157. Asn125 and Val76 are predicted to orient the C-terminal Cys5 residue of the substrate.
information alone, neither the substrate nor the actually
bound ¯avin cofactor, FMN or FAD, can be predicted
unambiguously. Perhaps the unusual binding mode of FAD
facilitated by intermolecular interactions between cofactors in
neighbouring molecules contributes to this uncertainty. The
biochemical function and properties have to be tested and
veri®ed experimentally in every single case. For example, the
function of the SIS2 protein of Saccharomyces cerevisiae
(Ferrando et al., 1995) with yet another composition of the
substrate-binding clamp (Blaesse et al., 2000) is still unknown.
The PPC decarboxylase reaction essential for coenzyme A
biosynthesis is likely to be the original function of the HFCD
family. Changes within the substrate-binding clamp of the PPC
decarboxylases resulted in loss of the second half-reaction and
enabled the oxidative decarboxylation of peptidyl-cysteines by
LanD enzymes, used by some lantibiotic-synthesizing systems.
The resulting enethiol structure retained in LanD-catalyzed
reactions and present in the unsaturated thioether rings of
lantibioticts such as epidermin and mersacidin contribute to
rigidity of these peptide antibiotics. Simultaneously, the
terminal carboxylate group of these lantibiotics is removed,
changing the net charge of these compounds. At the moment it
is not known if and how these properties (the unsaturated
thioether ring and the missing carboxylate group) contribute
to the mode of action of epidermin and mersacidin. It will be
interesting to learn whether nature has found yet another
application of the simple principle of oxidizing terminal
cysteines in a ¯avin-dependent reaction to make use of the
resulting chemistry.
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